Evaluation of LC-aNAAT melting curve PCR for simultaneous identification of Mycobacterium tuberculosis complex and rifampicin resistance
Frontiers in Microbiology · 20.11.2026 · 17
DOI: 10.3389/fmicb.2026.1992822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 20.11.2026. Verfasst von Xichao Ou und 14 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the performance of Genewise MTBC/RIF (Genewise) in comparison with Xpert MTB/RIF (Xpert) assay and phenotypic drug susceptibility testing for detection of Mycobacterium tuberculosis (MTB) and rifampcin (RIF) resistance.
Methods
Respiratory specimens stored at the National Tuberculosis Reference Laboratory between January 2023 and December 2024 were tested using the MGIT 960, Genewise and the Xpert assay. Phenotypic RIF susceptibility testing was performed on culture-positive isolates using the minimal inhibitory concentration method. Diagnostic performance was assessed for MTB detection and rifampicin resistance identification.
Results
The Genewise assay demonstrated a sensitivity for MTB detection of 96.76% against liquid culture, 97.22% against microbiological reference standard (MRS) and over 99% against Xpert. For RIF resistance detection, both the Genewise and Xpert assay exhibited a sensitivity of 91.67% and a specificity of 98.52%. Head-to-head comparison showed near-perfect agreement between Genewise and Xpert for both MTB (κ = 0.851) and RIF resistance detection (κ = 1.0). The inverse correlation between Genewise CT values and Xpert bacterial load grades supported its semi-quantitative capability, and ROC curve analysis confirmed comparable diagnostic performance to Xpert (AUC = 0.988).
Conclusion
The Genewise MTBC/RIF assay is a rapid, automated molecular test that detects MTBC with high sensitivity and identifies RIF resistance with performance comparable to Xpert, making it well-suited to a complementary diagnostic tool.
Zitieren
APA
Ou, X., Zhao, B., Zheng, Y., Guo, Y., Song, Y., Cui, K., Kang, J., Ma, Q., Xing, R., Li, J., Xia, H., Chen, Y., Zhou, Y., Zhao, Y., & Zheng, H. (2026). Evaluation of LC-aNAAT melting curve PCR for simultaneous identification of Mycobacterium tuberculosis complex and rifampicin resistance. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1992822
Vancouver
Ou X, Zhao B, Zheng Y, Guo Y, Song Y, Cui K, et al. Evaluation of LC-aNAAT melting curve PCR for simultaneous identification of Mycobacterium tuberculosis complex and rifampicin resistance. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1992822
BibTeX
@article{Ou2026,
author = {Ou, Xichao and Zhao, Bing and Zheng, Yang and Guo, Yajie and Song, Yuanyuan and Cui, Kai and Kang, Jie and Ma, Qi and Xing, Ruida and Li, Jingjing and Xia, Hui and Chen, Yuying and Zhou, Yang and Zhao, Yanlin and Zheng, Huiwen},
title = {Evaluation of LC-aNAAT melting curve PCR for simultaneous identification of Mycobacterium tuberculosis complex and rifampicin resistance},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1992822}
}
EUVIMED